Athena Diagnostics today filed its reply brief to Mayo Collaborative Services at the Supreme Court in the closely-watched petition asking the High Court to clarify U.S. patent eligibility law. The reply reiterates the points made in Athena’s petition for certiorari and dismisses Mayo’s argument in November that “any further action regarding the patentability of medical diagnostic claims such as Athena’s that employ conventional, known techniques should and does rest with Congress.” The reply comes three days after the United States Solicitor General recommended that SCOTUS grant cert in Athena or “another such case”, rather than in Hikma Pharmaceuticals v. Vanda Pharmaceuticals.
Litigation
- Justices Seek Abitron Parties’ Help in Articulating Bounds of Extraterritorial Application of Lanham Act
- U.S. Taxpayers Should Not Be Paying for Private Patent Infringement
- UK Court Hands Down Key FRAND Ruling in InterDigital v. Lenovo
- Litigation Trends, Shared Core Technologies Make Wi-Fi 6 an Attractive SEP Monetization Target (Part 1)
- Federal Circuit: Known Technique Addressing Known Problem Satisfies KSR’s Motivation to Combine Analysis
Recent Posts
- Justices Seek Abitron Parties’ Help in Articulating Bounds of Extraterritorial Application of Lanham Act
- U.S. Taxpayers Should Not Be Paying for Private Patent Infringement
- UK Court Hands Down Key FRAND Ruling in InterDigital v. Lenovo
- Litigation Trends, Shared Core Technologies Make Wi-Fi 6 an Attractive SEP Monetization Target (Part 1)
- Other Barks & Bites: UK Rules in InterDigital-Lenovo SEP Fight; USPTO to add FDA Info to PTE Page; Copyright Office Launches Initiative to Explore AI’s Implications on Copyright Law